MCID: SLT001
MIFTS: 38

Solitary Osseous Plasmacytoma

Categories: Cancer diseases, Immune diseases, Blood diseases, Bone diseases

Aliases & Classifications for Solitary Osseous Plasmacytoma

MalaCards integrated aliases for Solitary Osseous Plasmacytoma:

Name: Solitary Osseous Plasmacytoma 12 15 73
Isolated Osseous Plasmacytoma 12
Solitary Plasmacytoma of Bone 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3722
NCIt 50 C7812
SNOMED-CT 68 42215000 426336007
UMLS 73 C0272256

Summaries for Solitary Osseous Plasmacytoma

MalaCards based summary : Solitary Osseous Plasmacytoma, also known as isolated osseous plasmacytoma, is related to extramedullary plasmacytoma and plasmacytoma, and has symptoms including bone pain An important gene associated with Solitary Osseous Plasmacytoma is MYOM2 (Myomesin 2), and among its related pathways/superpathways are Cytokine Signaling in Immune system and NF-kappaB Signaling. The drugs Ketamine and Darbepoetin alfa have been mentioned in the context of this disorder. Affiliated tissues include bone, bone marrow and liver, and related phenotypes are Synthetic lethal with MLN4924 (a NAE inhibitor) and Synthetic lethal with MLN4924 (a NAE inhibitor)

Related Diseases for Solitary Osseous Plasmacytoma

Diseases related to Solitary Osseous Plasmacytoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 39)
# Related Disease Score Top Affiliating Genes
1 extramedullary plasmacytoma 30.8 B2M MYOM2
2 plasmacytoma 11.6
3 indolent myeloma 10.7 B2M MYOM2
4 amyloid tumor 10.6 B2M MYOM2
5 pericoronitis 10.6 CD19 NCAM1
6 rhinoscleroma 10.6 CD19 NCAM1
7 pancreatic serous cystadenoma 10.5 NCAM1 PTCRA
8 small intestine lymphoma 10.4 B2M CD19
9 extrahepatic bile duct adenocarcinoma 10.4 NCAM1 SDC1
10 functional colonic disease 10.4 B2M PTCRA
11 cloacogenic carcinoma 10.4 B2M CD27
12 invasive malignant thymoma 10.3 CD19 CD38
13 anterior scleritis 10.3 B2M CD19 NCAM1
14 colonic pseudo-obstruction 10.3 B2M PTCRA
15 b cell prolymphocytic leukemia 10.3 CD19 CD38
16 lung lymphoma 10.3 BIRC3 CD19 NCAM1
17 cavernous sinus thrombosis 10.2 PTCRA SDC1
18 anterior spinal artery syndrome 10.2 CD27 SDC1
19 gamma heavy chain disease 10.2 CD19 CD38
20 lymphoproliferative syndrome 2 10.2 CD27 MCL1
21 b cell deficiency 10.2 CD19 CD27
22 non-secretory myeloma 10.1 B2M CD38 MYOM2
23 plasma protein metabolism disease 10.1 CD19 CD38 MYOM2
24 juvenile glaucoma 10.0 PTCRA SDC1
25 b-cell expansion with nfkb and t-cell anergy 10.0 B2M CD38
26 amyloidosis 9.9
27 common variable immunodeficiency 9.8 CD19 CD27 CD38
28 prolymphocytic leukemia 9.8 CD19 CD38
29 diffuse infiltrative lymphocytosis syndrome 9.7 CD19 CD38 SDC1
30 human immunodeficiency virus infectious disease 9.6 B2M CD38
31 bone marrow cancer 9.5 B2M CD38 MYOM2 SDC1
32 hematologic cancer 9.5 CD19 CD38 MCL1 NCAM1
33 leukemia, acute myeloid 9.5 CD19 CD38 MCL1 NCAM1
34 monoclonal gammopathy of uncertain significance 9.4 B2M CD19 CD38 MYOM2 NCAM1
35 leukemia, chronic lymphocytic 9.0 B2M CD19 CD27 CD38 MCL1
36 plasma cell neoplasm 8.7 B2M CD19 CD38 MAEA MYOM2 NCAM1
37 mature b-cell neoplasm 8.4 B2M CD19 CD38 MAEA MYOM2 SDC1
38 lymphoma, non-hodgkin, familial 8.0 B2M BIRC3 CD19 CD27 CD38 MCL1
39 myeloma, multiple 7.5 B2M CD19 CD38 MAEA MCL1 MYOM2

Graphical network of the top 20 diseases related to Solitary Osseous Plasmacytoma:



Diseases related to Solitary Osseous Plasmacytoma

Symptoms & Phenotypes for Solitary Osseous Plasmacytoma

UMLS symptoms related to Solitary Osseous Plasmacytoma:


bone pain

GenomeRNAi Phenotypes related to Solitary Osseous Plasmacytoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-1 9.23 BIRC3 MAEA MCL1
2 Synthetic lethal with MLN4924 (a NAE inhibitor) GR00250-A-2 9.23 BIRC3 CD27 CD38 MAEA MCL1
3 Decreased viability after Chlamydia trachomatis serovar L2 infection and TNF-alpha/CHX stimulation GR00206-A 8.96 BIRC3 MCL1

MGI Mouse Phenotypes related to Solitary Osseous Plasmacytoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.76 MCL1 NCAM1 SDC1 B2M BIRC3 CD19
2 hematopoietic system MP:0005397 9.65 PTCRA SDC1 B2M BIRC3 CD19 CD27
3 immune system MP:0005387 9.32 MCL1 PTCRA SDC1 B2M BIRC3 CD19

Drugs & Therapeutics for Solitary Osseous Plasmacytoma

Drugs for Solitary Osseous Plasmacytoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 224)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Darbepoetin alfa Approved, Investigational Phase 3,Phase 2 11096-26-7, 209810-58-2
3
Iron Approved Phase 3,Phase 1,Phase 2 7439-89-6 23925
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Dalteparin Approved Phase 3 9005-49-6
6
Heparin Approved, Investigational Phase 3 9005-49-6 772 46507594
7
Ondansetron Approved Phase 3 99614-02-5 4595
8
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
9
Caspofungin Approved Phase 3,Phase 2 179463-17-3, 162808-62-0 468682 2826718
10
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 1,Phase 2,Not Applicable 22916-47-8 4189
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Guaifenesin Approved, Investigational, Vet_approved Phase 3,Not Applicable 93-14-1 3516
13
Morphine Approved, Investigational Phase 3,Not Applicable 57-27-2 5288826
14
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2 50-02-2 5743
15 Ixazomib Approved, Investigational Phase 3 1072833-77-2
16
Lenalidomide Approved Phase 3 191732-72-6 216326
17
Zoledronic acid Approved Phase 3 118072-93-8 68740
18
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
19
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
20
Citric Acid Approved, Nutraceutical, Vet_approved Phase 3 77-92-9 311
21
Glycine Approved, Nutraceutical, Vet_approved Phase 3 56-40-6 750
22 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
23 Analgesics Phase 3,Not Applicable
24 Anesthetics Phase 3
25 Anesthetics, Dissociative Phase 3
26 Anesthetics, General Phase 3
27 Anesthetics, Intravenous Phase 3
28 Central Nervous System Depressants Phase 3,Phase 1,Phase 2,Not Applicable
29 Excitatory Amino Acid Antagonists Phase 3
30 Excitatory Amino Acids Phase 3
31 Neurotransmitter Agents Phase 3
32 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
34 Ferric Compounds Phase 3
35 ferric gluconate Phase 3
36 Hematinics Phase 3,Phase 2
37 Analgesics, Opioid Phase 3,Not Applicable
38 Narcotics Phase 3,Not Applicable
39 Adjuvants, Anesthesia Phase 3
40 Liver Extracts Phase 3,Phase 1
41 Epoetin alfa Phase 3,Phase 2 113427-24-0
42 Hormones Phase 3,Phase 2,Phase 1
43 Anticoagulants Phase 3,Phase 1,Phase 2
44 calcium heparin Phase 3
45 Fibrinolytic Agents Phase 3
46 Heparin, Low-Molecular-Weight Phase 3
47 Anti-Anxiety Agents Phase 3
48 Antiemetics Phase 3,Phase 2,Phase 1
49 Antipruritics Phase 3
50 Antipsychotic Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 Darbepoetin Alfa With or Without Iron in Treating Anemia Caused By Chemotherapy in Patients With Cancer Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
3 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
4 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
5 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
6 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
7 Darbepoetin Alfa Compared With Epoetin Alfa in Treating Anemia in Patients Receiving Chemotherapy for Cancer Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
8 St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer Completed NCT00005805 Phase 3
9 Dalteparin to Prevent Complications in Cancer Patients Receiving Chemotherapy Through a Catheter Completed NCT00006083 Phase 3 Fragmin
10 Ondansetron in Treating Patients With Advanced Cancer and Chronic Nausea and Vomiting Not Caused by Cancer Treatment Completed NCT00006348 Phase 3 ondansetron
11 Caspofungin Acetate Compared With Amphotericin B Liposomal in Treating Patients With Persistent Fever and Neutropenia Following Cancer Treatment Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
12 Liposomal Amphotericin B in Treating Granulocytopenia and Persistent Unexplained Fever in Cancer Patients Completed NCT00003938 Phase 3 liposomal amphotericin B
13 Treatment for Chronic Pain in Patients With Advanced Cancer Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
14 Ixazomib Citrate, Lenalidomide, Dexamethasone, and Zoledronic Acid or Zoledronic Acid Alone After Radiation Therapy in Treating Patients With Solitary Plasmacytoma of Bone Recruiting NCT02516423 Phase 3 ixazomib;lenalidomide;dexamethasone;zoledronic acid
15 Beta Alethine in Treating Patients With Myeloma Unknown status NCT00006466 Phase 1, Phase 2 beta alethine
16 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
17 SWOG-9239 Reduction of Immunosuppression Plus Interferon Alfa and Combination Chemotherapy in Treating Patients With Malignant Tumors That Develop After Organ Transplant Completed NCT00002657 Phase 2 cyclophosphamide;cytarabine;doxorubicin hydrochloride;etoposide;methotrexate;prednisone;vincristine sulfate
18 Epoetin Alfa or Darbepoetin Alfa in Treating Patients With Anemia Caused by Chemotherapy Completed NCT00416624 Phase 2 darbepoetin alfa;epoetin alfa
19 Interleukin-2 Plus Interferon Alfa in Treating Adults With Metastatic Cancer Completed NCT00002504 Phase 2
20 Donor Natural Killer Cells After Donor Stem Cell Transplant in Treating Patients With Advanced Cancer Completed NCT00823524 Phase 1, Phase 2
21 Combination Chemotherapy Followed by Peripheral Stem Cell Transplantation in Treating Patients With Refractory Cancer Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide
22 Epoetin Alfa in Treating Patients With Anemia Who Are Undergoing Chemotherapy for Cancer Completed NCT00255749 Phase 2
23 Busulfan, Fludarabine, and Total-Body Irradiation in Treating Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00245037 Phase 1, Phase 2 busulfan;cyclosporine;fludarabine phosphate;mycophenolate mofetil;Granulocyte colony-stimulating factor (G-CSF);Phenytoin;Methotrexate
24 Non-Ablative Allo HSCT For Hematologic Malignancies or SAA Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
25 Caspofungin Acetate in Treating Aspergillosis in Patients With Hematologic Cancer or in Patients Who Have Undergone a Stem Cell Transplant Completed NCT00110045 Phase 2 caspofungin acetate
26 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005804 Phase 2 cyclophosphamide
27 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2
28 Peripheral Blood Lymphocyte Therapy to Prevent Lymphoproliferative Disorders Caused by Epstein-Barr Virus in Patients Who Have Undergone Transplantation Completed NCT00005606 Phase 2
29 Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma Active, not recruiting NCT01849783 Phase 2 dexamethasone;cisplatin;doxorubicin;cyclophosphamide;etoposide;bortezomib;thalidomide;melphalan
30 S0340 MRI and Fludeoxyglucose F18 PET in Diagnosing Solitary Plasmacytoma Terminated NCT00109889 Phase 2
31 Antimicrobial Solution or Saline Solution in Maintaining Catheter Patency and Preventing Catheter-Related Blood Infections in Patients With Malignancies Withdrawn NCT01101412 Phase 1, Phase 2 Edetate Calcium Disodium;Ethanol;Trimethoprim-sulfamethoxazole
32 Combination Chemotherapy Plus Amifostine in Treating Patients With Advanced Cancer Unknown status NCT00004036 Phase 1 amifostine trihydrate;carboplatin;cyclophosphamide
33 Sunitinib Malate in Treating HIV-Positive Patients With Cancer Receiving Antiretroviral Therapy Completed NCT00890747 Phase 1 sunitinib malate
34 Imatinib Mesylate in Treating Patients With Advanced Cancer and Liver Dysfunction Completed NCT00025415 Phase 1 imatinib mesylate
35 PS-341 in Treating Patients With Advanced Cancer Completed NCT00006362 Phase 1 bortezomib
36 Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Solid Tumors That Have Not Responded to Previous Therapy Completed NCT00005634 Phase 1 vorinostat
37 Decitabine in Treating Patients With Melanoma or Other Advanced Cancer Completed NCT00002980 Phase 1 decitabine
38 Interleukin-12 Followed by Interferon Alfa in Treating Patients With Advanced Cancer Completed NCT00003451 Phase 1
39 Combination Chemotherapy in Treating Patients With Advanced Cancer Completed NCT00003331 Phase 1 fluorouracil;leucovorin calcium;topotecan hydrochloride
40 Monoclonal Antibody Therapy in Treating Patients With Advanced Cancer Completed NCT00003082 Phase 1
41 Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00004904 Phase 1 cladribine;cyclophosphamide;etoposide;methylprednisolone;tacrolimus
42 EMD 121974 in Treating Patients With Locally Advanced or Metastatic Cancer Completed NCT00004258 Phase 1 cilengitide
43 Pyroxamide in Treating Patients With Advanced Cancer Completed NCT00042900 Phase 1 pyroxamide
44 Bone Marrow and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00004232 Phase 1 cyclosporine;methylprednisolone;prednisone
45 Motexafin Gadolinium and Doxorubicin in Treating Patients With Advanced Cancer Completed NCT00036790 Phase 1 doxorubicin hydrochloride;motexafin gadolinium
46 Vaccine Therapy in Preventing Cytomegalovirus Infection in Patients With Hematological Malignancies Undergoing Donor Stem Cell Transplant Active, not recruiting NCT01588015 Phase 1
47 12-O-Tetradecanoylphorbol-13-acetate in Treating Patients With Hematologic Cancer or Bone Marrow Disorder Terminated NCT00004058 Phase 1 tetradecanoylphorbol acetate
48 S0120, Studying Blood and Bone Marrow Samples From Patients With Monoclonal Gammopathy of Undetermined Significance, Multiple Myeloma, or Plasmacytoma Completed NCT00900263
49 Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant Completed NCT01199562 Not Applicable ganciclovir;valganciclovir;foscarnet sodium
50 Massage Therapy Given by Caregiver in Treating Quality of Life of Young Patients Undergoing Treatment for Cancer Completed NCT01053494 Not Applicable

Search NIH Clinical Center for Solitary Osseous Plasmacytoma

Genetic Tests for Solitary Osseous Plasmacytoma

Anatomical Context for Solitary Osseous Plasmacytoma

MalaCards organs/tissues related to Solitary Osseous Plasmacytoma:

41
Bone, Bone Marrow, Liver

Publications for Solitary Osseous Plasmacytoma

Articles related to Solitary Osseous Plasmacytoma:

# Title Authors Year
1
Gradenigo's syndrome as first presentation of solitary osseous plasmacytoma of the petrous apex. ( 24979569 )
2014
2
Solitary osseous plasmacytoma of the orbit with amyloidosis. ( 17237706 )
2007
3
Multifocal extramedullary plasmacytoma with paraproteinemia, pleural involvement and retroperitoneal lymphadenopathy: an uncommon pattern of relapse of solitary osseous plasmacytoma. ( 16496148 )
2006

Variations for Solitary Osseous Plasmacytoma

Expression for Solitary Osseous Plasmacytoma

Search GEO for disease gene expression data for Solitary Osseous Plasmacytoma.

Pathways for Solitary Osseous Plasmacytoma

Pathways related to Solitary Osseous Plasmacytoma according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.83 B2M BIRC3 CD27 MCL1 NCAM1
2 12.07 B2M CD19 CD38 NCAM1
3 11.32 CD19 CD38 NCAM1 SDC1
4 11.2 CD19 CD38 NCAM1
5 10.65 CD19 CD27 CD38 SDC1

GO Terms for Solitary Osseous Plasmacytoma

Cellular components related to Solitary Osseous Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular exosome GO:0070062 9.7 B2M CD19 CD27 CD38 IGLL5 NCAM1
2 cell surface GO:0009986 9.35 B2M CD27 CD38 NCAM1 SDC1
3 external side of plasma membrane GO:0009897 9.1 B2M CD19 CD27 IGLL5 NCAM1 SDC1

Biological processes related to Solitary Osseous Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell surface receptor signaling pathway GO:0007166 9.33 BIRC3 CD19 CD27
2 B cell receptor signaling pathway GO:0050853 9.13 CD19 CD38 IGLL5
3 negative regulation of apoptotic process GO:0043066 9.02 BIRC3 CD27 CD38 MAEA MCL1

Molecular functions related to Solitary Osseous Plasmacytoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cysteine-type endopeptidase inhibitor activity involved in apoptotic process GO:0043027 8.62 BIRC3 CD27

Sources for Solitary Osseous Plasmacytoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....